Watch More Highlights
Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. Pivotal phase II talquetamab data showed > 70% ORR in heavily pretreated patients with RRMM. High response rates were also seen in patients with prior T-cell redirection therapy. The safety profile was clinically manageable, with low rates of high-grade infections and talquetamab discontinuations (Abstract 8036).